Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InSite Vision

Executive Summary

Plans to file amended NDA for MethaSite (extended-release fluorometholone eyedrops) in first half of 1994, company reports in Aug. 27 prospectus for an initial public offering of 3 mil. shares. MethaSite was designated approvable by FDA in March 1990 for control of mild-to-moderate inflammation in the anterior segment of the eye. The Alameda, Calif. company subsequently conducted a second Phase III trial using "the 'blow, fill, seal' manufacturing process to be used for the commercial production of MethaSite," the prospectus states. Morgan Stanley and Robertson Stephens are underwriting the offering.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel